These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8447356)

  • 21. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study].
    Rossmanith WG; Wirth U; Gasser S; Thun B; Steffens D
    Zentralbl Gynakol; 1997; 119(11):538-44. PubMed ID: 9480608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P; Favilli S
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of two monophase oral contraceptives with desogestrel].
    Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
    Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hormonal contraception].
    Van Cauwenberge JR
    Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation and noncontraceptive uses of the new, low-dose oral contraceptive.
    Batzer FR
    J Reprod Med; 1984 Jul; 29(7 Suppl):503-12. PubMed ID: 6237195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety.
    Singh M; Thomas D; Singh R; Saxena BB; Ledger WJ
    Eur J Contracept Reprod Health Care; 1996 Sep; 1(3):285-92. PubMed ID: 9678128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The current status of oral contraceptive clinical development in Japan.
    Kuwabara Y
    Int J Fertil; 1989; 34 Suppl():18-20. PubMed ID: 2576251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Stone S
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():117-21. PubMed ID: 8260969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
    Daly L; Bonnar J
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):430-7. PubMed ID: 2142580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter study in Hungary with a 30 micrograms ethinylestradiol- and 150 micrograms desogestrel-containing monophasic oral contraceptive.
    Bruyniks N; Kovacs L; Rákóczi I
    Adv Contracept; 1994 Sep; 10(3):175-85. PubMed ID: 7863843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects on hemostasis of oral contraceptives containing desogestrel.
    Stubblefield PG
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1047-52. PubMed ID: 8447359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study of the low dose oral contraceptive novynette].
    Uchikova E; Milchev N
    Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The androgenicity of oral contraceptives: the young patient's concerns.
    Runnebaum B
    Int J Fertil; 1992; 37 Suppl 4():211-7. PubMed ID: 1362188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cycle control with desogestrel-containing oral contraceptives--comparison of a monophasic and triphasic regimen.
    Carr BR
    Int J Fertil Menopausal Stud; 1993; 38(5):274-9. PubMed ID: 8298666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
    Dieben TO; op ten Berg MT; Coelingh Bennink HJ
    Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
    Am J Obstet Gynecol; 1998 Jul; 179(1):S2-8. PubMed ID: 9704812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.